StreptAvax

StreptAvax is a multivalent recombinant subunit vaccine developed by ID Biomedical, under license from the University of Tennessee, for the prevention of Group A streptococcal (*Streptococcus pyogenes*) infections. The vaccine is composed of recombinant M protein fragments from multiple serotypes of Group A Streptococcus (GAS). It was specifically engineered to include protective epitopes while excluding those associated with the induction of autoimmune responses, such as rheumatic fever, which are linked to PARF (peptide associated with rheumatic fever) motifs. By early 2005, the vaccine had completed Phase II clinical trials in healthy adults, demonstrating safety and immunogenicity. However, the complexity of the multivalent formulation and the requirement for extensive pediatric testing influenced its subsequent development path.

Brand names

StreptAvax

Other names

26-valent Group A streptococcal vaccine26-valent M protein vaccine